dc.creatorAcosta, J.
dc.creatorFlores, P.
dc.creatorAlarcón, M.
dc.creatorGrande-Ortiz, M.
dc.creatorMoreno-Exebio, L.
dc.creatorPuyen, Z. M.
dc.date.accessioned2022-03-04T11:11:49Z
dc.date.accessioned2024-05-07T02:47:50Z
dc.date.available2022-03-04T11:11:49Z
dc.date.available2024-05-07T02:47:50Z
dc.date.created2022-03-04T11:11:49Z
dc.date.issued2022-01-01
dc.identifier10273719
dc.identifier10.5588/ijtld.21.0373
dc.identifierhttp://hdl.handle.net/10757/659237
dc.identifier18157920
dc.identifierInternational Journal of Tuberculosis and Lung Disease
dc.identifier2-s2.0-85123036570
dc.identifierSCOPUS_ID:85123036570
dc.identifier0000 0001 2196 144X
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9328179
dc.description.abstractBACKGROUND: Adherence to TB treatment and therefore treatment success could be improved using digital adherence technology. OBJECTIVE: To evaluate the effectiveness of a medication event reminder monitor system (MERM) on treatment success and treatment adherence in patients with drug-susceptible pulmonary TB in Perú. METHODS: This was an experimental, randomised, open-label, controlled study conducted among patients in the second phase of TB treatment. The intervention group received their medications through MERM with the support of a treatment monitor, whereas the control group used the usual strategy. Participants were followed until they completed the 54 doses of the second phase of treatment. RESULTS: The study included 53 patients in each group; four in the intervention group withdrew from the study. Treatment success was significantly more frequent in the MERM group (RR 1.15, 95% CI 1.02–1.30; P = 0.0322). There was no significant difference in the adherence outcomes; however, the percentage of patients who missed at least one dose and patients with more than 10% of total doses missed were lower in the intervention group. CONCLUSION: The use of MERM in the second phase of treatment showed a significant improvement in the treatment success rate in patients with drug-susceptible pulmonary TB.
dc.languageeng
dc.publisherInternational Union Against Tuberculosis and Lung Disease
dc.relationhttps://www.ingentaconnect.com/content/iuatld/ijtld/2022/00000026/00000001/art00009
dc.rightshttp://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International
dc.sourceUniversidad Peruana de Ciencias Aplicadas (UPC)
dc.sourceRepositorio Academico - UPC
dc.sourceInternational Journal of Tuberculosis and Lung Disease
dc.source26
dc.source1
dc.source44
dc.source49
dc.subjectDigital adherence technologies
dc.subjectDispenser pillbox
dc.subjectTreatment adherence
dc.subjectTreatment success
dc.titleA randomised controlled trial to evaluate a medication monitoring system for TB treatment
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución